These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 502975)

  • 1. Phase I evaluation of the combination 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962) and dianhydrogalactitol (DAG; NSC-132313) in patients with advanced neoplastic diseases.
    Creagan ET; Eagan RT; Rubin J
    Med Pediatr Oncol; 1979; 7(2):179-80. PubMed ID: 502975
    [No Abstract]   [Full Text] [Related]  

  • 2. Combination carmustine (BCNU) and dianhydrogalactitol in the treatment of primary brain tumors recurring after irradiation.
    Eagan RT; Dinapoli RP; Hermann RC; Groover RV; Layton DD; Scott M
    Cancer Treat Rep; 1982 Aug; 66(8):1647-9. PubMed ID: 7105055
    [No Abstract]   [Full Text] [Related]  

  • 3. Preliminary study of the combination, dianhydrogalactitol, cis-diaminedichloroplatinum (II), and VP-16-213 in patients with advanced cancer.
    Creagan ET; Eagan RT; Kvols LK
    Oncology; 1981; 38(5):260-1. PubMed ID: 7196561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of the combination of dianhydrogalactitol, doxorubicin, and cisplatin (DAP) in patients with advanced squamous cell lung cancer.
    Eagan RT; Frytak S; Nichols WC; Ingle JN; Creagan ET; Kvols LK
    Cancer Treat Rep; 1981; 65(5-6):517-9. PubMed ID: 7195306
    [No Abstract]   [Full Text] [Related]  

  • 5. Dianhydrogalactitol (NSC-132313): phase II study in solid tumors.
    de Jager R; Brugarolas A; Hansen H; Cavalli F; Ryssel H; Siegenthaler P; Clarysse A; Renard J; Kenis Y; Alberto P
    Eur J Cancer (1965); 1979 Jul; 15(7):971-4. PubMed ID: 385328
    [No Abstract]   [Full Text] [Related]  

  • 6. Phase II trial of dianhydrogalactitol in metastatic malignant melanoma: a Southwest Oncology Group study.
    Thigpen JT; Al-Sarraf M; Hewlett JS
    Cancer Treat Rep; 1979 Apr; 63(4):525-8. PubMed ID: 445506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metastatic retinoblastoma and L-phenylalanine mustard-dianhydrogalactitol.
    Helson L; Kitchin FD; Abramson D; Ellsworth RM
    Anticancer Res; 1982; 2(4):235-8. PubMed ID: 7149653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intensive 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), NSC #4366650 and cryopreserved autologous marrow transplantation for refractory cancer. A phase I-II study.
    Phillips GL; Fay JW; Herzig GP; Herzig RH; Weiner RS; Wolff SN; Lazarus HM; Karanes C; Ross WE; Kramer BS
    Cancer; 1983 Nov; 52(10):1792-802. PubMed ID: 6354414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Use of 1,2:5,6-dianhydrogalactitol in combination with maytansine in experimental tumor therapy].
    Fan YJ; Zhou J; Li M
    Yao Xue Xue Bao; 1983 Sep; 18(9):648-53. PubMed ID: 6677049
    [No Abstract]   [Full Text] [Related]  

  • 10. Phase I evaluation of dianhydrogalactitol (NSC-132313).
    Haas CD; Stephens RL; Hollister M; Hoogstraten B
    Cancer Treat Rep; 1976 May; 60(5):611-4. PubMed ID: 991150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemotherapeutic approaches to brain tumors. Experimental observations with dianhydrogalactitol and dibromodulcitol.
    Levin VA; Wheeler KT
    Cancer Chemother Pharmacol; 1982; 8(1):125-31. PubMed ID: 7094198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effects of 1,2:5,6-dianhydrogalactitol on the bone marrow stem cells in normal and melanoma-bearing mice (author's transl)].
    Fan YJ; Li M; Zhou J
    Zhongguo Yao Li Xue Bao; 1980 Dec; 1(2):112-5. PubMed ID: 6461181
    [No Abstract]   [Full Text] [Related]  

  • 13. Phase II trial of dianhydrogalactitol in advanced soft tissue and bony sarcomas: a Southwest Oncology Group study.
    Thigpen JT; Samson MK
    Cancer Treat Rep; 1979 Apr; 63(4):553-5. PubMed ID: 445509
    [No Abstract]   [Full Text] [Related]  

  • 14. Phase II evaluation of dianhydrogalactitol in the treatment of advanced endometrial adenocarcinoma: a Gynecologic Oncology Group Study.
    Stehman FB; Blessing JA; Delgado G; Louka M
    Cancer Treat Rep; 1983; 67(7-8):737-8. PubMed ID: 6871892
    [No Abstract]   [Full Text] [Related]  

  • 15. [Drug formulation of a cytostatic compound and testing of the parenteral preparation].
    Stampf G; Kaszáné TE; Czirják F; Dávid A
    Acta Pharm Hung; 1982 Sep; 52(5):193-9. PubMed ID: 7148474
    [No Abstract]   [Full Text] [Related]  

  • 16. Phase II study of 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU, NSC No. 409962) with amphotericin B in bronchogenic carcinoma.
    Presant CA; Hillinger S; Klahr C
    Cancer; 1980 Jan; 45(1):6-10. PubMed ID: 6243243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amphotericin B plus 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU-NSC no. 409962) in advanced cancer. Phase I and preliminary phase II results.
    Presant CA; Klahr C; Olander J; Gatewood D
    Cancer; 1976 Nov; 38(5):1917-21. PubMed ID: 991105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II evaluation of dianhydrogalactitol in advanced head and neck carcinomas.
    Edmonson JH; Frytak S; Letendre L; Kvols LK; Eagan RT
    Cancer Treat Rep; 1979; 63(11-12):2081-3. PubMed ID: 526941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II evaluation of galactitol in head and neck cancer: a Southwest Oncology Group Study.
    Haas CD; Lehane D; Bottomley R
    Med Pediatr Oncol; 1983; 11(4):281-3. PubMed ID: 6888328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro cellular characteristics and survival responses of human astrocytoma clones to chloroethyl-nitrosoureas and dianhydrogalactitol.
    Rubin NH; Casartelli C; Macik BG; Boerwinkle WR; Barranco SC
    Invest New Drugs; 1983; 1(2):129-37. PubMed ID: 6678862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.